Iron Supplementation in CKD Stage 4 with Anemia

Dosing Recommendations

The National Kidney Foundation recommends that adult CKD stage 4 patients take 200 mg of elemental iron per day, divided into 2 to 3 doses, for iron supplementation 1, 2, 3, 4, 5

Iron should be taken on an empty stomach without food or other medications for maximum absorption, as recommended by the American Journal of Kidney Diseases 2, 3, 4, 5
Food consumed within 2 hours before or 1 hour after iron supplementation reduces absorption by up to 50%, according to the American Journal of Kidney Diseases 2, 3, 4, 5
Aluminum-based phosphate binders also impair iron absorption and should be separated from iron dosing, as stated in the American Journal of Kidney Diseases 2, 3, 4, 5

The American Journal of Kidney Diseases suggests using ionic iron salts (ferrous sulfate, fumarate, or gluconate) as they are the most cost-effective and provide known amounts of elemental iron 2, 3, 4, 5
Ferrous sulfate 325 mg tablets contain 65 mg elemental iron, as reported in the American Journal of Kidney Diseases 4, 5
Ferrous fumarate 325 mg tablets contain 108 mg elemental iron, according to the American Journal of Kidney Diseases 4, 5
Ferrous gluconate 325 mg tablets contain 35 mg elemental iron, as stated in the American Journal of Kidney Diseases 4, 5
Iron polysaccharide is more expensive and not better tolerated or more effective than ionic iron salts, as reported in the American Journal of Kidney Diseases 2, 3, 4, 5

Most CKD patients may not maintain adequate iron status with oral iron alone, according to the American Journal of Kidney Diseases 1, 6
If oral iron fails after 1-3 months, switching to intravenous iron may be necessary, as suggested in the American Journal of Kidney Diseases 1, 6

If gastrointestinal side effects occur with twice-daily dosing, consider smaller, more frequent doses, starting with lower doses and gradually increasing, trying a different iron salt preparation, or taking the supplement at bedtime, as recommended in the American Journal of Kidney Diseases 2, 3, 4, 5

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend that for adult CKD patients not on dialysis, including those with stage IV, clinicians may choose either IV iron or a 1-3 month trial of oral iron therapy, with IV iron being the preferred first-line choice when feasible 7, 8

For CKD stage IV patients requiring iron supplementation, a 1-3 month trial of oral iron is an acceptable alternative to IV iron, but IV iron should be the first-line choice when feasible, as stated by the KDIGO guidelines 7, 8

Iron supplementation should be initiated in CKD stage IV patients when TSAT ≤30% and ferritin ≤500 ng/mL, to increase hemoglobin without starting ESA therapy, according to the KDIGO guidelines 7, 8, 9
The goal of iron therapy is to avoid transfusion or improve anemia-related symptoms in CKD stage IV patients 7, 8

For CKD stage IV patients on iron therapy, hemoglobin should be checked at least every 3 months, and TSAT and ferritin should be checked at least every 3 months once treatment is established, as recommended by the KDIGO guidelines 7, 8, 9
Iron supplementation should be stopped when ferritin >500 ng/mL or TSAT >50%, as patients are unlikely to respond with further hemoglobin increases beyond these thresholds 9, 10, 11

The KDIGO guidelines recommend a step-wise approach to iron management in CKD stage IV, including checking iron status, choosing an iron route based on severity of iron deficiency and availability of venous access, and monitoring response to therapy 7, 8
If choosing oral iron, it should be prescribed for 1-3 months, and TSAT and ferritin should be rechecked after the trial, with a switch to IV iron if there is an inadequate response 7, 8
If choosing IV iron, it should be administered as a trial course, with monitoring of hemoglobin response and adjustment of subsequent dosing based on response 7, 8, 9

The American Journal of Kidney Diseases recommends that oral iron fails to maintain adequate iron stores in most hemodialysis patients and many advanced CKD patients, resulting in persistence of moderate anemia which increases morbidity and mortality 12, 13
The American Journal of Kidney Diseases suggests that there is no rationale for prescribing oral iron supplements when IV iron is required, given oral iron's inconvenience, cost, and side effects in the context of its poor efficacy 12, 13

High-dose IV iron (>200 mg/month) has been associated with increased risk of acute cardiocerebrovascular disease, infections, and mortality, as reported in the journal Drugs 14